Onyvax starts Phase II cancer vaccine trial

Onyvax (London, U.K.) said it started an open-label 30-patient U.K. Phase II trial of Onyvax P therapeutic vaccine to treat patients with prostate cancer refractory to hormone replacement therapy. In ...